Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03539107 · ClinicalTrials.gov registry record · NA
Voiding Assessment Based on Minimum Spontaneous Void of 150 mL Compared to Retrograde Fill Method After Female Pelvic Floor Reconstructive Surgery
A NA study of Urinary Incontinence and Pelvic Organ Prolapse, sponsored by Yale University.
- Completed
- Registry status
- NA
- Development phase
- 110
- Enrollment target
- 1
- Study location
NCT03539107: Completed NA study of Urinary Incontinence and Pelvic Organ Prolapse, sponsored by Yale University.
NCT03539107 is a NA study of Urinary Incontinence and Pelvic Organ Prolapse that has completed, run by Yale University. The registered enrollment target is 110 participants, below the 260-participant average among 48 other Urinary Incontinence trials with a reported enrollment target (58% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03539107, a NA study of Urinary Incontinence and Pelvic Organ Prolapse, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- NA
- Development phase
- 110 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will compare voiding assessment based on a minimum spontaneous voided volume of 150 cc with the standard retrograde fill approach in women after pelvic floor procedures.
Primary Outcome
The percentage of subjects who did not meet the required voiding assessment criteria and needed catheterization .
Conditions Studied
Interventions
- PROCEDURE Retrograde bladder fill
- OTHER spontaneous void
Study Locations (1)
Connecticut
- Yale University - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2019-09-01 |
| Est. Completion | 2019-12-20 |
| Phase | NA |
What the finished NCT03539107 record still lists
NCT03539107 is an interventional study that assigns participants to a tested intervention. The registered 110 participants enrollment target is mid-sized for trials with a published cap, below the 260-participant average among 48 other Urinary Incontinence trials with a reported enrollment target (58% lower).
The record links to 2 conditions, with Urinary Incontinence appearing as the primary indexed condition, and to 2 interventions - of which Retrograde bladder fill is the first listed.
NCT03539107 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT03539107 about?
NCT03539107 is a clinical study titled "Voiding Assessment Based on Minimum Spontaneous Void of 150 mL Compared to Retrograde Fill Method After Female Pelvic Floor Reconstructive Surgery". This study will compare voiding assessment based on a minimum spontaneous voided volume of 150 cc with the standard retrograde fill approach in women after pelvic floor procedures.
What is the current status of trial NCT03539107?
This trial is currently completed. It is a NA study. The enrollment target is 110 participants. The study started on 2019-09-01. Estimated completion is 2019-12-20.
What conditions does trial NCT03539107 study?
This clinical trial studies the following conditions: Urinary Incontinence, Pelvic Organ Prolapse.
What interventions are being tested in trial NCT03539107?
The interventions under investigation include: Retrograde bladder fill (PROCEDURE), spontaneous void (OTHER).
Who is sponsoring clinical trial NCT03539107?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03539107 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Urinary Incontinence
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03539107's enrollment target sits among peer trials
110 23rd of 48 higher than 26 of 48 other Urinary Incontinence trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Urinary Incontinence trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Trial of Transurethral Bulking Agent Injection Versus Single-Incision Sling for Stress Urinary Incontinence
RECRUITING · NA
-
TENS Analgesia During Outpatient Urethral Bulking for Stress Urinary Incontinence.
RECRUITING · NA
-
Adjustable Continence Therapy (ACT) for the Treatment of Female SUI
RECRUITING · NA
-
Improving Overactive Bladder Treatment Access and Adherence
RECRUITING · NA
-
Training for Urinary Leakage Improvement After Pregnancy
RECRUITING · NA
-
Home Biofeedback Therapy for Dyssynergic Defecation, Fecal Incontinence and Urinary Incontinence
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01530373 · 110 participants · Phase 2
Solifenacin Compared to Clonidine for Reducing Hot Flashes Among Breast Cancer Patients
- NCT02379377 · 110 participants · Phase 1
18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant
- NCT02411773 · 110 participants · Phase 1
Sympatholysis in Chronic Kidney Disease
- NCT03190941 · 110 participants · Phase 1
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI